MedTrace Logo

Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn

NCT03237442 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-08-02

No results posted yet for this study

Summary

Ocular chemical burn is one of the causes of vision loss in China, and there are no satisfactory treatment. Human umbilical cord mesenchymal stem cells(UC-MSCs) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rabbits, the UC-MSCs can accelerated the cornea repair, inhibited angiogenesis. The aim of this study is to access the efficacy and safety of UC-MSCs in the treatment of corneal burn in human.

Conditions

  • Ocular Corneal Burn

Interventions

BIOLOGICAL

human umbilical cord mesenchymal stem cells

human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection

BIOLOGICAL

placebo

Saline injection

Sponsors & Collaborators

  • Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-12-30
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237442 on ClinicalTrials.gov